Marc Krause

Marc Krause

Auto-generated profile, based on publicly available information

Marc Krause

Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2018 in European Archives of Psychiatry and Clinical Neuroscience
Verified
Journal Article
Closed access
PDF file
MKMarc Krause
Marc Krause
YZYikang Zhu
Yikang Zhu
MHMaximilian Huhn
Maximilian Huhn
JSJohannes Schneider-Thoma
Johannes Schneider-Thoma
IBIrene Bighelli
Irene Bighelli
SLStefan Leucht
Stefan Leucht

7 September 2018 in World Psychiatry
Verified
Journal Article
Open access
PDF file
IBIrene Bighelli
Irene Bighelli
GSGeorgia Salanti
Georgia Salanti
MHMaximilian Huhn
Maximilian Huhn
JSJohannes Schneider‐Thoma
Johannes Schneider‐Thoma
MKMarc Krause
Marc Krause
SLStefan Leucht
Stefan Leucht
Psychological treatments are increasingly regarded as useful interventions for schizophrenia. However, a comprehensive evaluation of the available evidence is lacking and the benefit of psychological interventions for patients with current positive symptoms is still debated. The present study aimed to evaluate the efficacy, acceptability and tolerability of psychological treatments for positive symptoms of schizophrenia by applying a network meta‐analysis approach, that can integrate direct and indirect comparisons. We searched EMBASE, MEDLINE, PsycINFO, PubMed, BIOSIS, Cochrane Library, World Health Organization's International Clinical Trials Registry Platform and ClinicalTrials.gov for randomized controlled trials of psychological treatments for positive symptoms of schizophrenia, published up to January 10, 2018. We included studies on adults with a diagnosis of schizophrenia or a related disorder presenting positive symptoms. The primary outcome was change in positive symptoms measured with validated rating scales. We included 53 randomized controlled trials of seven psychological interventions, for a total of 4,068 participants receiving the psychological treatment as add‐on to antipsychotics. On average, patients were moderately ill at baseline. The network meta‐analysis showed that cognitive behavioural therapy (40 studies) reduced positive symptoms more than inactive control (standardized mean difference, SMD=−0.29; 95% CI: –0.55 to −0.03), treatment as usual (SMD=−0.30; 95% CI: –0.45 to −0.14) and supportive therapy (SMD=−0.47; 95% CI: –0.91 to −0.03). Cognitive behavioural therapy was associated with a higher dropout rate compared with treatment as usual (risk ratio, RR=0.74; 95% CI: 0.58 to 0.95). Confidence in the estimates ranged from moderate to very low. The other treatments contributed to the network with a lower number of studies. Results were overall consistent in sensitivity analyses controlling for several factors, including the role of researchers’ allegiance and blinding of outcome assessor. Cognitive behavior therapy seems to be effective on positive symptoms in moderately ill patients with schizophrenia, with effect sizes in the lower to medium range, depending on the control condition.

1 September 2017 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
YZYikang Zhu
Yikang Zhu
CLChunbo Li
Chunbo Li
MHMaximilian Huhn
Maximilian Huhn
PRPhilipp Rothe
Philipp Rothe
MKMarc Krause
Marc Krause
SLStefan Leucht
Stefan Leucht

1 June 2018 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
MKMarc Krause
Marc Krause
YZYikang Zhu
Yikang Zhu
MHMaximilian Huhn
Maximilian Huhn
JSJohannes Schneider-Thoma
Johannes Schneider-Thoma
IBIrene Bighelli
Irene Bighelli
SLStefan Leucht
Stefan Leucht

1 September 2017 in The Lancet Psychiatry
Verified
Journal Article
Closed access
YZYikang Zhu
Yikang Zhu
MKMarc Krause
Marc Krause
MHMaximilian Huhn
Maximilian Huhn
PRPhilipp Rothe
Philipp Rothe
JSJohannes Schneider-Thoma
Johannes Schneider-Thoma
SLStefan Leucht
Stefan Leucht

1 January 2019 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
MKMarc Krause
Marc Krause
MHMaximilian Huhn
Maximilian Huhn
JSJohannes Schneider-Thoma
Johannes Schneider-Thoma
IBIrene Bighelli
Irene Bighelli
KGKatharina Gutsmiedl
Katharina Gutsmiedl
SLStefan Leucht
Stefan Leucht